
Piotr Rieske

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3817769/publications.pdf Version: 2024-02-01



PIOTO PIESKE

#	Article	IF	CITATIONS
1	Generation of human iPSCs from cells of fibroblastic and epithelial origin by means of the oriP/EBNA-1 episomal reprogramming system. Stem Cell Research and Therapy, 2015, 6, 122.	5.5	66
2	Human fibroblast-derived cell lines have characteristics of embryonic stem cells and cells of neuro-ectodermal origin. Differentiation, 2005, 73, 474-483.	1.9	59
3	A population of human brain parenchymal cells express markers of glial, neuronal and early neural cells and differentiate into cells of neuronal and glial lineages. European Journal of Neuroscience, 2007, 25, 31-37.	2.6	52
4	AKT Induces Transcriptional Activity of PU.1 through Phosphorylation-mediated Modifications within Its Transactivation Domain. Journal of Biological Chemistry, 2001, 276, 8460-8468.	3.4	47
5	EGFR ^{vIII} : An Oncogene with Ambiguous Role. Journal of Oncology, 2019, 2019, 1-20.	1.3	45
6	Arrested neural and advanced mesenchymal differentiation of glioblastoma cells-comparative study with neural progenitors. BMC Cancer, 2009, 9, 54.	2.6	40
7	Directed differentiation of human iPSC into insulin producing cells is improved by induced expression of PDX1 and NKX6.1 factors in IPC progenitors. Journal of Translational Medicine, 2016, 14, 341.	4.4	35
8	EGFR Activation Leads to Cell Death Independent of PI3K/AKT/mTOR in an AD293 Cell Line. PLoS ONE, 2016, 11, e0155230.	2.5	31
9	Screening for EGFR Amplifications with a Novel Method and Their Significance for the Outcome of Glioblastoma Patients. PLoS ONE, 2013, 8, e65444.	2.5	29
10	High incidence of MGMT promoter methylation in primary glioblastomas without correlation with TP53 gene mutations. Cancer Genetics and Cytogenetics, 2009, 188, 77-82.	1.0	28
11	Glioblastoma-derived spheroid cultures as an experimental model for analysis of EGFR anomalies. Journal of Neuro-Oncology, 2011, 102, 395-407.	2.9	27
12	Mutational analysis of hSNF5/INI1 and TP53 genes in choroid plexus carcinomas. Cancer Genetics and Cytogenetics, 2005, 156, 179-182.	1.0	25
13	Efficient and simple approach to <i>inÂvitro</i> culture of primary epithelial cancer cells. Bioscience Reports, 2016, 36, .	2.4	24
14	CYP46: A risk factor for Alzheimer's disease or a coincidence?. Neuroscience Letters, 2005, 383, 105-108.	2.1	23
15	Assessment of <i>OPG</i> / <i>RANK</i> / <i>RANKL</i> Gene Expression Levels in Peripheral Blood Mononuclear Cells (PBMC) After Treatment With Strontium Ranelate and Ibandronate in Patients With Postmenopausal Osteoporosis. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1007-E1011.	3.6	23
16	Cell line with endogenous EGFRvIII expression is a suitable model for research and drug development purposes. Oncotarget, 2016, 7, 31907-31925.	1.8	23
17	Atypical molecular background of glioblastoma and meningioma developed in a patient with Li?Fraumeni syndrome. Journal of Neuro-Oncology, 2005, 71, 27-30.	2.9	22
18	The Failure in the Stabilization of Glioblastoma-Derived Cell Lines: Spontaneous In Vitro Senescence as the Main Culprit. PLoS ONE, 2014, 9, e87136.	2.5	22

PIOTR RIESKE

#	Article	IF	CITATIONS
19	Regulation of PrPC expression: Nerve growth factor (NGF) activates the prion gene promoter through the MEK1 pathway in PC12 cells. Neuroscience Letters, 2006, 400, 58-62.	2.1	19
20	Multiple Myeloma in a Patient with Systemic Lupus Erythematosus, Myasthenia Gravis and Non-Familial Diffuse Palmoplantar Keratoderma. Leukemia and Lymphoma, 2004, 45, 1913-1918.	1.3	18
21	IDH1R132H in Neural Stem Cells: Differentiation Impaired by Increased Apoptosis. PLoS ONE, 2016, 11, e0154726.	2.5	18
22	SOX2 and SOX2-MYC Reprogramming Process of Fibroblasts to the Neural Stem Cells Compromised by Senescence. PLoS ONE, 2015, 10, e0141688.	2.5	14
23	Synthesis and physicochemical characterization of chitin dihexanoate — A new biocompatible chitin derivative — In comparison to chitin dibutyrate. Materials Science and Engineering C, 2016, 60, 489-502.	7.3	14
24	Sensitivity of neoplastic cells to senescence unveiled under standard cell culture conditions. Anticancer Research, 2015, 35, 2759-68.	1.1	14
25	Richter's Syndrome in the Brain First Manifested as an Ischaemic Stroke. Leukemia and Lymphoma, 2004, 45, 1261-1267.	1.3	13
26	A population of human brain cells expressing phenotypic markers of more than one lineage can be induced in vitro to differentiate into mesenchymal cells. Experimental Cell Research, 2009, 315, 462-473.	2.6	13
27	Reduced expression of ELAVL4 in male meningioma patients. Brain Tumor Pathology, 2013, 30, 160-166.	1.7	13
28	Diverse molecular pattern in a bihemispheric glioblastoma (butterfly glioma) in a 16-year-old boy. Cancer Genetics and Cytogenetics, 2007, 177, 125-130.	1.0	12
29	cDNA sequencing improves the detection of P53 missense mutations in colorectal cancer. BMC Cancer, 2009, 9, 278.	2.6	12
30	Low Incidence along with Low mRNA Levels of EGFRvIII in Prostate and Colorectal Cancers Compared to Glioblastoma. Journal of Cancer, 2017, 8, 146-151.	2.5	12
31	Spontaneous in vitro senescence of glioma cells confirmed by an antibody against IDH1R132H. Anticancer Research, 2014, 34, 2859-67.	1.1	12
32	Chitin dipentanoate as the new technologically usable biomaterial. Materials Science and Engineering C, 2015, 55, 50-60.	7.3	11
33	Successful elimination of non-neural cells and unachievable elimination of glial cells by means of commonly used cell culture manipulations during differentiation of GFAP and SOX2 positive neural progenitors (NHA) to neuronal cells. BMC Biotechnology, 2008, 8, 56.	3.3	10
34	Gaps and Doubts in Search to Recognize Glioblastoma Cellular Origin and Tumor Initiating Cells. Journal of Oncology, 2020, 2020, 1-15.	1.3	10
35	KCTD11 expression in medulloblastoma is lower than in adult cerebellum and higher than in neural stem cells. Cancer Genetics and Cytogenetics, 2006, 170, 24-28.	1.0	9
36	Neuronal and astrocytic cells, obtained after differentiation of human neural GFAP-positive progenitors, present heterogeneous expression of PrPc. Brain Research, 2007, 1186, 65-73.	2.2	9

PIOTR RIESKE

#	Article	IF	CITATIONS
37	Prevalence of mutated TP53 on cDNA (but not on DNA template) in pleomorphic xanthoastrocytoma with positive TP53 immunohistochemistry. Cancer Genetics and Cytogenetics, 2009, 193, 93-97.	1.0	9
38	A way to understand idiopathic senescence and apoptosis in primary glioblastoma cells– possible approaches to circumvent these phenomena. BMC Cancer, 2019, 19, 923.	2.6	9
39	Curcumin modulates airway remodellingâ€contributing genes—the significance of transcription factors. Journal of Cellular and Molecular Medicine, 2022, 26, 736-749.	3.6	8
40	Limited importance of the dominant-negative effect of TP53missense mutations. BMC Cancer, 2011, 11, 243.	2.6	7
41	Cyclic trans-phosphorylation in a homodimer as the predominant mechanism of EGFRvIII action and regulation. Oncotarget, 2018, 9, 8560-8572.	1.8	6
42	Loss of heterozygosity for Rb locus and pRb immunostaining in laryngeal cancer: a clinicopathologic, molecular and immunohistochemical study Folia Histochemica Et Cytobiologica, 2009, 46, 479-85.	1.5	6
43	Multiomic analysis on human cell model of wolfram syndrome reveals changes in mitochondrial morphology and function. Cell Communication and Signaling, 2021, 19, 116.	6.5	6
44	Detection of P53 mutations in different cancer types is improved by cDNA sequencing. Oncology Letters, 2010, 1, 717-721.	1.8	5
45	Generation of induced neural stem cells with inducible IDH1R132H for analysis of glioma development and drug testing. PLoS ONE, 2020, 15, e0239325.	2.5	5
46	PIN3 duplication may be partially responsible for TP53haploinsufficiency. BMC Cancer, 2014, 14, 669.	2.6	4
47	Molecular alterations in meningiomas: association with clinical data. , 2013, 32, 114-121.		4
48	EGFRvIIIa stable target for anti-EGFRvIII therapy. Anticancer Research, 2013, 33, 5343-8.	1.1	4
49	Application and Design of Switches Used in CAR. Cells, 2022, 11, 1910.	4.1	4
50	Glioblastoma specimens with TP53 mutations do not show EGFRvIII amplification. Cancer Genetics, 2011, 204, 282-283.	0.4	3
51	Role of Senescence in Tumorigenesis and Anticancer Therapy. Journal of Oncology, 2022, 2022, 1-23.	1.3	3
52	Different mutational characteristics of TSG in cell lines and surgical specimens. Tumor Biology, 2014, 35, 11311-11318.	1.8	2
53	Genetic heterogeneity of RPMI-8402, a T-acute lymphoblastic leukemia cell line. Oncology Letters, 2016, 11, 593-599.	1.8	2
54	Gliomas: association of histology and molecular genetic analysis of chromosomes 1p, 10q, and 19q. Acta Neurobiologiae Experimentalis, 2007, 67, 103-12.	0.7	1

#	Article	IF	CITATIONS
55	Regeneration difficulties in patients with FQAD can limit the use of iPSc-based cell therapy. Stem Cell Research and Therapy, 2022, 13, .	5.5	1